Global R&D Pipeline
My Favorite
Hot Targets:
IL4
Back
Total number of drugs
30
Phase II and later clinical stages
6.7%
Involving companies
29
Main therapeutic areas
Immune System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PF-07275315 | PF-07275315 | Trispecific antibody | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases Respiratory Diseases | IL-13 inhibitors IL-4 inhibitors TSLP inhibitors | Pfizer Inc. | Pfizer Inc. | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | PF-07275315 | - | - | detail > | |
| BSI-501 | BSI-501 | Bispecific antibody | Immune System Diseases | IL-13 inhibitors IL-4 inhibitors | Biosion, Inc. | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | BSI-501 | - | - | detail > | |
| Pascolizumab | Pascolizumab | Monoclonal antibody | Immune System Diseases Respiratory Diseases | IL-4 inhibitors | GSK Plc | - | Discontinued (in Phase 2) | - | - | - | - | - | - | - | - | - | Pascolizumab | - | - | detail > | |
| IL-4R(Aradigm) | IL-4R(Aradigm) | Cytokines | Immune System Diseases Respiratory Diseases | IL-4 modulators | Aradigm Corp. | - | Discontinued (in Phase 2) | - | - | - | - | - | - | - | - | - | IL-4R(Aradigm) | - | - | detail > | |
| CN120842236 | CN120842236 | Small molecule drug | Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases Other Diseases | IL-13 inhibitors IL-4 inhibitors IgE inhibitors TNF-α inhibitors TSLP inhibitors | Kunming Medical University | Kunming Medical University | Discovery | - | - | - | - | - | - | - | - | - | CN120842236 | - | - | detail > | |
| CN118164939 | CN118164939 | Small molecule drug | Immune System Diseases Respiratory Diseases Other Diseases | - | First Affiliated Hospital of Henan University of Traditional Chinese Medicine | First Affiliated Hospital of Henan University of Traditional Chinese Medicine | Discovery | - | - | - | - | - | - | - | - | - | CN118164939 | - | - | detail > | |
| CN116041454 | CN116041454 | Fusion protein | Infectious Diseases | - | National Institute for Communicable Disease Control and Prevention | National Institute for Communicable Disease Control and Prevention | Discovery | - | - | - | - | - | - | - | - | - | CN116041454 | - | - | detail > | |
| CN116239639 | CN116239639 | Small molecule drug | Respiratory Diseases | - | 江门市大健康国际创新研究院 Wuyi University | 江门市大健康国际创新研究院 Wuyi University | Discovery | - | - | - | - | - | - | - | - | - | CN116239639 | - | - | detail > | |
| PF-07264660 | PF-07264660 | Trispecific antibody | Immune System Diseases Congenital Disorders Skin and Musculoskeletal Diseases | IL-13 inhibitors IL-33 inhibitors IL-4 inhibitors | Pfizer Inc. | Pfizer Inc. | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | PF-07264660 | - | - | detail > | |
| IL-4/IL-13 kinoid(Neovacs) | IL-4/IL-13 kinoid(Neovacs) | Therapeutic vaccine Conjugated vaccine | Immune System Diseases Respiratory Diseases | IL-13 inhibitors IL-4 inhibitors | Neovacs SA | Neovacs SA | Preclinical | - | - | - | - | - | - | - | - | - | IL-4/IL-13 kinoid(Neovacs) | - | - | detail > |
Total 30 data
1
2
3
